JO2634B1 - Compounds that have activity on the M1 receptor and their uses in medicines - Google Patents
Compounds that have activity on the M1 receptor and their uses in medicinesInfo
- Publication number
- JO2634B1 JO2634B1 JO2006342A JOP20060342A JO2634B1 JO 2634 B1 JO2634 B1 JO 2634B1 JO 2006342 A JO2006342 A JO 2006342A JO P20060342 A JOP20060342 A JO P20060342A JO 2634 B1 JO2634 B1 JO 2634B1
- Authority
- JO
- Jordan
- Prior art keywords
- fluorine atoms
- compounds
- substituted
- alkyl
- receptor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000017927 CHRM1 Human genes 0.000 title 1
- 101150073075 Chrm1 gene Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- -1 C1-6 aIkoxy Chemical group 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0519950.0A GB0519950D0 (en) | 2005-09-30 | 2005-09-30 | Compounds |
| GB0602040A GB0602040D0 (en) | 2006-02-01 | 2006-02-01 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO2634B1 true JO2634B1 (en) | 2012-06-17 |
Family
ID=37598231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JO2006342A JO2634B1 (en) | 2005-09-30 | 2006-09-28 | Compounds that have activity on the M1 receptor and their uses in medicines |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8283364B2 (https=) |
| EP (1) | EP1943230B1 (https=) |
| JP (1) | JP5209480B2 (https=) |
| KR (2) | KR101374458B1 (https=) |
| CN (1) | CN101321736B (https=) |
| AR (1) | AR056103A1 (https=) |
| AT (1) | ATE492537T1 (https=) |
| AU (1) | AU2006296369B2 (https=) |
| BR (1) | BRPI0616609A2 (https=) |
| CA (1) | CA2624504C (https=) |
| CR (1) | CR9904A (https=) |
| DE (1) | DE602006019119D1 (https=) |
| EA (1) | EA016286B1 (https=) |
| IL (1) | IL190219A (https=) |
| JO (1) | JO2634B1 (https=) |
| MA (1) | MA29849B1 (https=) |
| MY (1) | MY148504A (https=) |
| NO (1) | NO20081945L (https=) |
| NZ (1) | NZ566508A (https=) |
| PE (1) | PE20070490A1 (https=) |
| TW (1) | TWI389905B (https=) |
| UA (1) | UA101299C2 (https=) |
| WO (1) | WO2007036715A2 (https=) |
| ZA (1) | ZA200802167B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007036711A1 (en) | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR |
| WO2007036718A2 (en) | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
| US8283364B2 (en) | 2005-09-30 | 2012-10-09 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
| US7766829B2 (en) * | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
| GB0605785D0 (en) * | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
| GB0706165D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706170D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706164D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706174D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0718415D0 (en) * | 2007-09-20 | 2007-10-31 | Glaxo Group Ltd | Compounds |
| WO2009124882A1 (en) * | 2008-04-09 | 2009-10-15 | H. Lundbeck A/S | Novel piperidinyl-1,3-dihydro-benzoimidazol-2-ones as m1 agonists |
| GB0817982D0 (en) | 2008-10-01 | 2008-11-05 | Glaxo Group Ltd | Compounds |
| WO2016073294A1 (en) * | 2014-11-03 | 2016-05-12 | William Beaumont Hospital | Method for treating underactive bladder syndrome |
| KR20170141769A (ko) * | 2015-04-29 | 2017-12-26 | 얀센 파마슈티카 엔.브이. | 인돌론 화합물 및 ampa 수용체 조절제로서의 이의 용도 |
| ES2865330T3 (es) | 2015-04-29 | 2021-10-15 | Janssen Pharmaceutica Nv | Azabenzimidazoles y su uso como moduladores del receptor AMPA |
| CA2996717A1 (en) | 2015-09-11 | 2017-03-16 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| CN107673994A (zh) * | 2017-04-27 | 2018-02-09 | 联化科技股份有限公司 | 一种芳基甲烷类化合物的制备方法 |
| CN107739342B (zh) * | 2017-11-29 | 2020-01-10 | 华南理工大学 | 一种一步合成5-二芳氨基苯并咪唑酮衍生物的方法 |
| CN117049938B (zh) * | 2023-06-20 | 2024-06-14 | 山东轩德医药科技有限公司 | 一种6-溴-2,3-二氟甲苯的制备方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3161645A (en) * | 1962-12-18 | 1964-12-15 | Res Lab Dr C Janssen N V | 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds |
| US3989707A (en) * | 1974-06-21 | 1976-11-02 | Janssen Pharmaceutica N.V. | Benzimidazolinone derivatives |
| US4292321A (en) * | 1979-05-24 | 1981-09-29 | Warner-Lambert Company | 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof |
| DE3124366A1 (de) * | 1981-06-20 | 1982-12-30 | Hoechst Ag, 6000 Frankfurt | N-oxacyclyl-alkylpiperidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung |
| DE4040300A1 (de) | 1990-12-17 | 1992-07-02 | Leifeld Gmbh & Co | Drueckmaschine mit wenigstens einem rollenhalter |
| JP3916093B2 (ja) * | 1993-09-17 | 2007-05-16 | 杏林製薬株式会社 | 光学活性イミダゾリジノン誘導体とその製造方法 |
| JP2002515008A (ja) * | 1994-10-27 | 2002-05-21 | メルク エンド カンパニー インコーポレーテッド | ムスカリン・アンタゴニスト |
| US5574044A (en) * | 1994-10-27 | 1996-11-12 | Merck & Co., Inc. | Muscarine antagonists |
| US5691323A (en) * | 1995-05-12 | 1997-11-25 | Merck & Co., Inc. | Muscarine antagonists |
| AU7478396A (en) | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Muscarine agonists |
| US5718912A (en) * | 1996-10-28 | 1998-02-17 | Merck & Co., Inc. | Muscarine agonists |
| US5977134A (en) * | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6465484B1 (en) * | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
| US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU2307999A (en) * | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| US6699880B1 (en) | 1999-10-13 | 2004-03-02 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
| SE9904652D0 (sv) * | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| WO2001057019A1 (en) * | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa |
| EP1385518B1 (en) * | 2001-04-18 | 2008-08-06 | Euro-Celtique S.A. | Benzimidazolone compounds |
| JPWO2002085890A1 (ja) * | 2001-04-20 | 2004-08-12 | 萬有製薬株式会社 | ベンズイミダゾロン誘導体 |
| WO2004089942A2 (en) * | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| BR0213611A (pt) * | 2001-10-02 | 2005-12-20 | Acadia Pharm Inc | Composto, composição farmacêutica, seus usos, método para aumentar a atividade de um receptor colinérgico, métodos para tratamento ou prevenção de distúrbio mental, dor, pressão intraocular aumentada e progressão ou formação de placas amilóides |
| US6951849B2 (en) * | 2001-10-02 | 2005-10-04 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| CA2465328C (en) * | 2001-11-01 | 2011-06-14 | Michael Francis Gross | Piperidines |
| JP4056977B2 (ja) | 2002-03-29 | 2008-03-05 | 田辺三菱製薬株式会社 | 睡眠障害治療薬 |
| EP1515722A4 (en) | 2002-06-17 | 2006-06-21 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
| US7645771B2 (en) | 2002-12-13 | 2010-01-12 | Smithkline Beecham Corp. | CCR5 antagonists as therapeutic agents |
| JP2005102133A (ja) | 2003-04-28 | 2005-04-14 | Ricoh Co Ltd | 画像形成装置及び宛先情報参照方法 |
| WO2005009996A1 (en) * | 2003-07-23 | 2005-02-03 | Wyeth | Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands |
| UA86204C2 (uk) * | 2003-09-03 | 2009-04-10 | Пфайзер Инк. | Сполуки бензімідазолону, які мають 5-нт4 рецепторну агоністичну активність |
| ES2318556T3 (es) * | 2004-11-02 | 2009-05-01 | Pfizer, Inc. | Derivados de sulfonil bencimidazol. |
| US7300947B2 (en) * | 2005-07-13 | 2007-11-27 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
| WO2007036711A1 (en) | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR |
| US8283364B2 (en) | 2005-09-30 | 2012-10-09 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
| WO2007036718A2 (en) | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
| CA2662333C (en) | 2006-09-08 | 2013-12-31 | The Gillette Company | Toothbrush with multiple bristle states |
| GB0706190D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706174D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706168D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706187D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706164D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706167D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706189D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706188D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706173D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706165D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706170D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
-
2006
- 2006-09-27 US US12/088,465 patent/US8283364B2/en not_active Expired - Fee Related
- 2006-09-27 NZ NZ566508A patent/NZ566508A/en not_active IP Right Cessation
- 2006-09-27 MY MYPI20080901A patent/MY148504A/en unknown
- 2006-09-27 AT AT06794584T patent/ATE492537T1/de not_active IP Right Cessation
- 2006-09-27 AU AU2006296369A patent/AU2006296369B2/en not_active Ceased
- 2006-09-27 JP JP2008532866A patent/JP5209480B2/ja not_active Expired - Fee Related
- 2006-09-27 WO PCT/GB2006/003590 patent/WO2007036715A2/en not_active Ceased
- 2006-09-27 KR KR1020087007797A patent/KR101374458B1/ko not_active Expired - Fee Related
- 2006-09-27 CN CN2006800451692A patent/CN101321736B/zh not_active Expired - Fee Related
- 2006-09-27 BR BRPI0616609-1A patent/BRPI0616609A2/pt not_active IP Right Cessation
- 2006-09-27 DE DE602006019119T patent/DE602006019119D1/de active Active
- 2006-09-27 EA EA200801001A patent/EA016286B1/ru not_active IP Right Cessation
- 2006-09-27 UA UAA200803937A patent/UA101299C2/uk unknown
- 2006-09-27 EP EP06794584A patent/EP1943230B1/en active Active
- 2006-09-27 KR KR1020137020049A patent/KR20130091791A/ko not_active Ceased
- 2006-09-27 CA CA2624504A patent/CA2624504C/en not_active Expired - Fee Related
- 2006-09-28 TW TW095135887A patent/TWI389905B/zh not_active IP Right Cessation
- 2006-09-28 AR ARP060104268A patent/AR056103A1/es unknown
- 2006-09-28 PE PE2006001183A patent/PE20070490A1/es not_active Application Discontinuation
- 2006-09-28 JO JO2006342A patent/JO2634B1/en active
-
2007
- 2007-09-10 US US11/852,455 patent/US8481566B2/en not_active Expired - Fee Related
-
2008
- 2008-03-17 IL IL190219A patent/IL190219A/en not_active IP Right Cessation
- 2008-04-04 MA MA30812A patent/MA29849B1/fr unknown
- 2008-04-18 CR CR9904A patent/CR9904A/es unknown
- 2008-04-23 NO NO20081945A patent/NO20081945L/no not_active Application Discontinuation
-
2009
- 2009-03-07 ZA ZA200802167A patent/ZA200802167B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO2634B1 (en) | Compounds that have activity on the M1 receptor and their uses in medicines | |
| SG170752A1 (en) | Benzimidazoles which have activity at m1 receptor and their uses in medicine | |
| MX2013005826A (es) | Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion. | |
| NZ630721A (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | |
| NZ613219A (en) | Heterocyclic containing entities, compositions and methods | |
| TN2012000071A1 (en) | Heterocyclic compounds and uses thereof | |
| PT1940839E (pt) | Inibidores de piridopirimidinona pi3k alfa | |
| MX2012003539A (es) | Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac). | |
| NZ706506A (en) | Heterocyclic compounds and uses thereof | |
| NO20090580L (no) | Syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer | |
| MX339823B (es) | Ingenol-3-acilatos iii e ingenol-3-carbamatos. | |
| UA86602C2 (ru) | Применение соединений антагониста crth2 в терапии | |
| MX347917B (es) | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. | |
| PH12013502369A1 (en) | Diazacarbazoles and methods of use | |
| IL202617A0 (en) | Pyrimidyl cyclopentanes as akt protein kinase inhibitors | |
| NO20071438L (no) | 4-arylspirosykloalky 1-2-aminopyrimidinkarboksamid KCNQ kaliumkanal modulerende forbindelser | |
| MY148375A (en) | Delta and epsilon crystal forms of imatinib mesylate | |
| MXPA06009475A (es) | Derivados de quinazolina y usos terapeuticos de los mismos. | |
| NO20080445L (no) | Nye azetidinderivater som neurokininreseptorantagonister for behandling av gastrointestinale sykdommer | |
| WO2007036718A3 (en) | Compounds which have activity at m1 receptor and their uses in medicine | |
| EA200970936A1 (ru) | СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА | |
| TW200704640A (en) | Pyrazolecarboxamides | |
| WO2014060852A3 (en) | Compounds useful in the synthesis of benzamide compounds | |
| EA201101207A1 (ru) | Применение антагонистов рецептора nk | |
| UA114017C2 (xx) | Похідні аміноциклобутану, спосіб їх одержання та їх застосування як лікарських засобів |